Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Organon & Co. (OGN)

Organon & Co. (OGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,856,279
  • Shares Outstanding, K 259,983
  • Annual Sales, $ 6,403 M
  • Annual Income, $ 864,000 K
  • EBIT $ 1,203 M
  • EBITDA $ 1,480 M
  • 60-Month Beta 0.57
  • Price/Sales 0.30
  • Price/Cash Flow 1.48
  • Price/Book 2.09

Options Overview Details

View History
  • Implied Volatility 57.06% (+2.48%)
  • Historical Volatility 94.40%
  • IV Percentile 69%
  • IV Rank 40.10%
  • IV High 91.71% on 11/05/25
  • IV Low 33.87% on 01/21/25
  • Expected Move (DTE 14) 0.48 (6.79%)
  • Put/Call Vol Ratio 4.28
  • Today's Volume 1,473
  • Volume Avg (30-Day) 2,813
  • Put/Call OI Ratio 0.86
  • Today's Open Interest 95,734
  • Open Int (30-Day) 110,569
  • Expected Range 6.66 to 7.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.73
  • Number of Estimates 2
  • High Estimate 0.76
  • Low Estimate 0.69
  • Prior Year 0.83
  • Growth Rate Est. (year over year) -12.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.33 +12.80%
on 11/06/25
7.88 -9.39%
on 11/14/25
+0.76 (+11.91%)
since 11/05/25
3-Month
6.18 +15.53%
on 10/30/25
11.29 -36.76%
on 10/03/25
-3.24 (-31.21%)
since 09/05/25
52-Week
6.18 +15.53%
on 10/30/25
17.23 -58.56%
on 02/13/25
-8.42 (-54.11%)
since 12/05/24

Most Recent Stories

More News
3 Value Stocks with Questionable Fundamentals

3 Value Stocks with Questionable Fundamentals

IRDM : 17.74 (+1.14%)
ANGI : 13.91 (+7.25%)
OGN : 7.14 (unch)
3 Cash-Producing Stocks We Find Risky

3 Cash-Producing Stocks We Find Risky

HLMN : 8.82 (-1.89%)
OGN : 7.14 (unch)
REGN : 718.36 (-0.61%)
Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings?

Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings?

OGN : 7.14 (unch)
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks

Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks

OGN : 7.14 (unch)
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Organon (NYSE: OGN), announced today that Joe Morrissey, Interim Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler...

OGN : 7.14 (unch)
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY ...

OGN : 7.14 (unch)
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call

The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call

OGN : 7.14 (unch)
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Organon ...

OGN : 7.14 (unch)
Organon (OGN) Stock Trades Down, Here Is Why

Organon (OGN) Stock Trades Down, Here Is Why

OGN : 7.14 (unch)
OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration

OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration

OGN : 7.14 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Organon is a healthcare company. It focuses on the health of women throughout their lives. Organon is based in JERSEY CITY, N.J.

See More

Key Turning Points

3rd Resistance Point 7.35
2nd Resistance Point 7.27
1st Resistance Point 7.21
Last Price 7.14
1st Support Level 7.06
2nd Support Level 6.98
3rd Support Level 6.91

See More

52-Week High 17.23
Fibonacci 61.8% 13.01
Fibonacci 50% 11.70
Fibonacci 38.2% 10.40
Last Price 7.14
52-Week Low 6.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar